SCHEMBL4868573

SCHEMBL4868573

Fc1ccc(Nc2nc(-c3ccccc3)nc3ccccc23)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 13/20 1.00
MEN1 O00255 3/20 0.84
KMT2A Q03164 3/20 0.84
PDE5A O76074 2/20 0.82
MAPT P10636 2/20 0.78
LMNA P02545 2/20 0.78
TP53 P04637 1/20 0.78
GAA P10253 1/20 0.78
CYP1A2 P05177 2/20 0.77
CYP3A4 P08684 2/20 0.77
HSD17B10 Q99714 2/20 0.77
KDM4E B2RXH2 1/20 0.77
HPGD P15428 1/20 0.77
TSHR P16473 1/20 0.77
MAPK1 P28482 1/20 0.77
CYP2C19 P33261 1/20 0.77
TDP1 Q9NUW8 1/20 0.77
KDM1A O60341 2/20 0.75
TGFBR1 P36897 1/20 0.75
MAPK14 Q16539 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1063103 0.92 ABCG2 (1.00) ABCG2MEN1KMT2APDE5AMAPT
SCHEMBL22201578 0.91 HPGD (0.86) ABCG2MEN1KMT2APDE5AMAPT
SCHEMBL14262835 0.89 ABCG2 (0.82) ABCG2MEN1KMT2APDE5AMAPT
SCHEMBL413202 0.88 TGFBR1 (0.86) ABCG2MEN1KMT2APDE5AMAPT
SCHEMBL8095812 0.88 ABCG2 (1.00) ABCG2MEN1KMT2APDE5AMAPT
SCHEMBL1061916 0.88 ABCG2 (1.00) ABCG2MEN1KMT2APDE5AMAPT
SCHEMBL4867505 0.88 ABCG2 (1.00) ABCG2MEN1KMT2APDE5AMAPT
SCHEMBL412953 0.86 TGFBR1 (1.00) ABCG2MEN1KMT2APDE5AMAPT
SCHEMBL31061048 0.86 TGFBR1 (1.00) ABCG2MEN1KMT2APDE5AMAPT
SCHEMBL13945468 0.85 ABCG2 (1.00) ABCG2MEN1KMT2APDE5AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R ABCG2 207/4885MEN1 3837/4885KMT2A 1662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.